Safety and tolerability of a single administration of AR-301, a human monoclonal antibody, in ICU patients with severe pneumonia caused by Staphylococcus aureus : first-in-human trial

ConclusionsAdjunctive treatment of severeS. aureus HABP with anti-staphylococcal mAbs appears feasible and suggests some clinical benefits, but larger randomized studies are needed to better define its safety and efficacy.

Source: Intensive Care Medicine - October 21, 2018 Category: Intensive Care Source Type: research